SCHEDULE: Citadel Discloses 5.8% Stake in Inspire Medical Systems

Citadel and its affiliates, including Kenneth Griffin, have disclosed a combined beneficial ownership of 5.8% in Inspire Medical Systems, Inc., signaling a significant passive investment.

Summary

• Citadel and its affiliated entities, including Kenneth Griffin, have reported beneficial ownership of Inspire Medical Systems, Inc. common stock.
• Kenneth Griffin is deemed to beneficially own 1,713,042 shares, representing 5.8% of the outstanding class.
• Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC each beneficially own 1,379,861 shares, or 4.7% of the class.
• Citadel Securities LLC beneficially owns 114,245 shares, or 0.4% of the class.
• Citadel Securities Group LP and Citadel Securities GP LLC each beneficially own 333,181 shares, or 1.1% of the class.
• The investment is classified as passive, not intended to change or influence control of the issuer.
• The percentages are based on 29,574,316 shares outstanding as of July 30, 2025, as reported in the issuer's Form 10-Q.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a major institutional investor like Citadel, led by Kenneth Griffin, is generally a positive signal for the company, indicating confidence in its value and prospects without seeking to influence control.

Positives

• A major institutional investor, Citadel, and its principal, Kenneth Griffin, have taken a significant stake in Inspire Medical Systems, Inc.
• The aggregate beneficial ownership by Kenneth Griffin of 5.8% indicates confidence in the company's long-term prospects from a prominent financial firm.
• The investment is classified as passive, suggesting a belief in the current management and strategic direction without seeking control.

Negatives

• No specific negative information regarding Inspire Medical Systems, Inc. is contained within this ownership disclosure.

Risks

• This ownership disclosure does not detail specific risks related to Inspire Medical Systems, Inc.'s operations or financial health.
• Investment in the company's shares carries inherent market risks, which are not elaborated upon in this filing.

Future Outlook

This Schedule 13G filing does not provide any forward-looking statements or guidance regarding Inspire Medical Systems, Inc.'s future performance or strategic outlook.

Management Comments

• This filing does not contain any direct quotes or paraphrased statements from Inspire Medical Systems, Inc. management.

Industry Context

The disclosure of a significant passive stake by a prominent hedge fund like Citadel in a medical device company like Inspire Medical Systems, Inc. can be viewed as a vote of confidence in the sector's growth potential, particularly in innovative healthcare solutions. This type of investment often signals that large institutional players see value and future appreciation in the company's market position and technology, aligning with broader trends of increasing investment in specialized healthcare technologies.

Comparison to Industry Standards

• This filing is an ownership disclosure and does not contain information that allows for a direct comparison of Inspire Medical Systems, Inc.'s operational or financial results against global industry benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investment may increase investor confidence and potentially attract more institutional interest, potentially supporting share price stability or growth.
• Management: A passive stake from a major investor like Citadel suggests an endorsement of the current management and strategic direction, reducing immediate pressure for operational changes.
• Employees, Customers, Suppliers, Creditors: This ownership disclosure is unlikely to have a direct or immediate impact on these stakeholders, as it does not involve operational changes, financial restructuring, or strategic shifts.

Next Steps

• This filing does not outline any specific future actions, events, or milestones for Inspire Medical Systems, Inc. or the reporting persons beyond the ongoing passive investment.

Key Dates

Recommendation

The disclosure of a significant passive stake by a reputable institutional investor like Citadel is a positive indicator, suggesting underlying value and potential for future appreciation. However, a Schedule 13G filing primarily reports ownership and does not provide new operational or financial performance data to warrant an immediate 'buy' recommendation. It reinforces a 'hold' position for existing investors and suggests further due diligence for potential new investors, as the investment is passive and does not imply active engagement to drive immediate change.

Keywords

Inspire Medical Systems, Citadel, Kenneth Griffin, Schedule 13G, Beneficial Ownership, Medical Devices, Healthcare, Institutional Investment, Passive Investment